U
VIRX

UBS’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

UBS’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.18M Buy
784
+553
+239% +$801K ﹤0.01% 3431
2014
Q2 		$316K Buy
231
+113
+96% +$131K ﹤0.01% 4677
2014
Q1 		$163K Buy
+118
New +$137K ﹤0.01% 5429

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UBS's VIRX Position: Q3 2014 in Review

UBS increased its Viracta Therapeutics, Inc. Common Stock (VIRX) stake by 51% in Q3 2014, buying an estimated $1.74M and bringing the position to 3,550 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

UBS first reported a position in VIRX in Q2 2013 and has held it in 6 quarters since. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

  • UBS held 3,550 shares of Viracta Therapeutics, Inc. Common Stock worth $5.32M as of Q3 2014.
  • UBS bought 1,205 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $1.74M.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #1965 holding.
  • UBS first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • 104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.